Background {#Sec1}
==========

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer death in the United States \[[@CR1], [@CR2]\]. Pulmonary high-grade neuroendocrine carcinoma (HGNEC), including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), is a heterogeneous group of poorly differentiated neoplasms and covers 20% of all lung cancers. Remarkably, these two subtypes have relatively similar histological, genetic, and clinical characteristics, such as higher incidence in males and heavy smokers, as well as high mitotic rate and necrosis at histologic examination. It is also widely believed that they have similarly poor overall survival \[[@CR3]\].

Cancer survivors have been increasing due to the improvement in diagnostic modalities and treatment of cancers. Second primary malignancy (SPM) is one of the most severe long-term complications in the population of cancer survivors. Several studies have demonstrated that patients with initial primary lung cancer have a higher risk of developing second primary lung cancer \[[@CR4]\]. According to research done by Wu and coworkers, the incidence of SPMs among patients with non-small cell lung cancer is about 6.4%. Furthermore, their findings indicated that 50.7% of SPMs occurred during the first year after the diagnosis of non-small cell lung cancer \[[@CR5]\]. However, the risk of SPMs following a diagnosis of lung HGNEC remains unclear.

In this context, we aimed to assess the risk of developing SPM in patients with pulmonary HGNEC in the United States utilizing the Surveillance, Epidemiology, and End Results (SEER) database. We obtained the standardized incidence ratio (SIR) of SPM after diagnosis of pulmonary HGNEC between January 2000 and December 2016. The incidence of SPMs stratified by age, sex, race, and latency was also analyzed. Additionally, multivariate Cox regression model was applied to investigate the factors affecting overall survival (OS) and cancer-specific survival (CSS) in patients with SPMs.

Methods {#Sec2}
=======

We obtained data on lung HGNEC patients from the SEER database, which collects cancer incidence and survival data from 18 regional cancer registries. These registries represent about 26% of the U.S. population. Using a 6-month minimum interval, as is required to exclude synchronous primary cancers, we identified cases of histologically confirmed HGNEC with primary site codes (C34.0-main bronchus; C34.1-upper lobe, lung; C34.2-middle lobe, lung; C34.3-lower lobe, lung; C34.8-overlapping lesion of the lung; and C34.9-lung, NOS) and ICD-0-3 Hist/Behav (8002/3: malignant tumour, small cell type; 8013/3: Large-cell neuroendocrine carcinoma; 8041/3: small cell carcinoma, NOS; 8042/3: oat cell carcinoma; 8043/3: small cell carcinoma, fusiform cell; 8044/3: small cell carcinoma, intermediate cell; and 8045/3: combined small cell carcinoma). Patients with no histologically confirmed cancer, and those diagnosed only based on autopsy/death certificate were excluded as were those under the age of 20 years. After the exclusion of patients who did not have active follow-up, 75,877 patients were ultimately eligible for inclusion into the present investigation.

We collected data on patient demographics (age, gender, and ethnicity), treatment (radiotherapy and chemotherapy), HGNECs (cancer site and histological subtype) and survival (survival period, vital status, and cause-specific death classification). We utilized SEER\*Stat multiple primary-standardized incidence ratio (MP-SIR) software version 8.3.5 ([[www.seer.cancer.gov/seerstat]{.ul}](http://www.seer.cancer.gov/seerstat)), to calculate the SIR and absolute excess risk (AER) for SPM occurrence. An SPM is defined as a metachronous cancer that develops at least 6 months after the first cancer diagnosis, according to the methods used previously. We estimated SIR as the ratio of the number of incident cases of cancers in patients with pulmonary HGNEC to the number of expected cases in the U.S. general population. SIR over 1.0 indicated that more cases were observed than would be expected. AER was calculated as the excess number of SPMs in patients with pulmonary HGNEC per 10,000 person-years at risk. We performed subgroup analyses by further stratifying patients according to their age at diagnosis, gender, ethnicity, calendar-years, and months of follow-up since the diagnosis of cancer.

Multivariate Cox regression analyses, which could identify the associations between different clinical characteristics and survival, were performed to estimate hazard ratios (HRs) and the associated 95% confidence intervals (CIs). All statistical tests were two-sided, and *P* values less than 0.05 were assumed to be significant. Our data were obtained from the SEER program and imported into SPSS software, and data analyses were performed using IBM SPSS statistics for Windows, version 23 (IBM Corp, Armonk, New York, USA).

Results {#Sec3}
=======

Between 2000 and 2016, 75,877 patients were diagnosed with pulmonary HGNEC and met inclusion criteria. 72,381 patients with small cell carcinoma and 3496 patients with large-cell neuroendocrine carcinoma were included. A total of 1161 cases with primary pulmonary HGNEC, including 1022 SCLC and 139 LCNEC, developed a cohort of 1361 SPMs. Among those with SMPs, 979 patients had only 1 SPM, and 182 had more than 2 SPMs. The demographic characteristics of both groups are displayed in Table [1](#Tab1){ref-type="table"}. Table 1Demographics of patientsDemographySCLCLCNECNumber/Median%/RangeNumber/Median%/Range**Total patients**72,3813496Sex Male36,40650.30%192855.15% Female35,97549.70%156844.85%Race White63,19287.30%291983.50% Black62848.68%42312.10% Other/unknown29054.01%1544.41%**Total patients with SPM**10221.41%1393.98%Sex Male45844.81%6848.92% Female56455.19%7151.08%Race White89987.96%11381.29% Black858.32%1913.67% Other/unknown383.72%75.04%**Patients with 1 SPM**8621.20%1173.35%Sex Male38444.55%5748.72% Female47855.45%6051.28%Race White75587.59%9682.05% Black748.58%1512.82% Other/unknown333.83%65.13%**Patients with 2 or more SPM**1600.23%220.63%Sex Male7446.25%1150% Female8653.75%1150%Race White14389.38%1777.27% Black127.50%418.18% Other/unknown53.12%14.55%**Age for SPM (median)**64 years(36-88 years)66 years(37-82 years)**Latency (median)**3.58 years(0.5--16.42 years)3.33 years(0.67-15 years)**Follow-up (median)**5.42 years(0.5--16.92 years)5.92 years(0.67--15.75 years)

Overall risk of SPM {#Sec4}
-------------------

This cohort had a trend of higher SPM incidence than expected in the general population (SIR 1.53; 95% CI, 1.45 to 1.62; AER 83.11). Site-specific analyses of SIRs indicated the highest risk of malignancy in the acute monocytic leukemia (SIR 10.51; 95% CI, 2.86 to 26.92), followed by acute myeloid leukemia (SIR 6.62; 95% CI, 4.85 to 8.83), acute non-lymphocytic leukemia (SIR 6.46; 95% CI, 4.8 to 8.52), oropharynx (SIR 6.24; 95% CI, 2.03 to 14.57), and acute lymphocytic leukemia (SIR 5.26; 95% CI, 1.43 to 13.46). However, AER was the highest for the respiratory system (AER 88.64), followed by digestive system (AER 10.85), and myeloid and monocytic leukemia (AER 7.81). The risk of developing SPM in patients with SCLC and LCNEC are summarized in Table [2](#Tab2){ref-type="table"}. Table 2Total SPMSiteAll cancerssmall cell lung cancerlarge cell neuroendocrine cancerOEO/E95% CIExcess riskOEO/E95% CIExcess riskOEO/E95% CIExcess riskAll sites1361887.491.531.45--1.6283.111195804.211.491.4--1.5775.2816683.271.991.7--2.32163.46All solid tumours1241790.411.571.48--1.6679.081083716.61.511.42--1.670.5815873.812.141.82--2.5166.34Oral cavity and pharynx3020.081.501.01--2.131.742818.11.551.03--2.241.9121.971.020.12--3.680.07 Floor of Mouth, and Gum and Other Mouth134.083.191.7--5.451.57133.693.521.88--6.021.7900.390.000.00--9.54−0.76 Pharynx82.862.791.21--5.510.972.582.711.09--5.580.8510.283.590.09--20.021.43Digestive System227165.171.371.2--1.5710.85201149.431.351.17--1.549.932615.751.651.08--2.4220.26 Esophagus179.321.821.06--2.921.35168.391.911.09--3.11.4710.941.060.03--5.930.12 Colon and Rectum11384.021.341.11--1.625.0910076.281.311.07--1.594.57137.741.680.89--2.8710.39 Anus, Anal Canal and Anorectum83.192.511.08--4.940.8452.91.720.56--4.020.430.2910.442.15--30.55.36 Pancreas4625.961.771.3--2.363.524123.421.751.26--2.383.3952.541.970.64--4.594.85Respiratory System650144.984.484.15--4.8488.64564131.354.293.95--4.6683.348613.636.315.05--7.79142.99 Larynx206.922.891.77--4.462.3196.253.041.83--4.752.4610.671.480.04--8.260.64 Lung and Bronchus627136.64.594.24--4.9686.07543123.794.394.03--4.7780.758412.826.555.23--8.12140.65Breast86122.170.700.56--0.87−6.3574112.390.660.52--0.83−7.39129.781.230.63--2.144.38 Female Breast86121.110.710.57--0.88−6.1674111.440.660.52--0.83−7.21129.671.240.64--2.174.61Female Genital System2047.090.420.26--0.66−4.761943.350.440.26--0.68−4.6913.740.270.01--1.49−5.42 Corpus and Uterus, NOS426.930.150.04--0.38−4.02424.80.160.04--0.41− 4.0102.130.000--1.73−4.21Male Genital System59144.850.410.31--0.53−15.0749130.360.380.28--0.5−15.671014.490.690.33--1.27−8.87 Prostate57143.350.400.3--0.52−15.1647129.020.360.27--0.48− 15.81014.330.700.33--1.28−8.56Urinary System11776.031.541.27--1.847.1910468.351.521.24--1.846.87137.681.690.9--2.8910.51 Urinary Bladder6845.071.511.17--1.914.025940.431.461.11--1.883.5894.641.940.89--3.688.61 Kidney and Renal Pelvis4728.991.621.19--2.163.164326.151.641.19--2.213.2542.841.410.38--3.612.3All Lymphatic and Hematopoietic Diseases9575.861.251.01--1.533.368868.461.291.03--1.583.7677.410.950.38--1.95−0.8 Lymphoma2438.880.620.4--0.92−2.612335.140.650.41--0.98−2.3413.740.270.01--1.49−5.41 Myeloma513.460.370.12--0.87−1.49412.120.330.09--0.84−1.5611.340.750.02--4.15−0.68 Leukemia6623.522.812.17--3.577.466121.192.882.2--3.77.6752.332.150.7--5.015.28\*O, observed numbers; E, expected numbers

A significantly increased risk was seen for different malignancies among two histology groups. Patients with SCLC were at excess risk of developing digestive system cancers (SIR 1.35; 95% CI, 1.17 to 1.54) and respiratory system cancers (SIR 4.29; 95% CI, 3.95 to 4.66). Similar risk trends were observed, where patients with pulmonary LCNEC had statistically significant excess risk for the development of the digestive system and respiratory system cancers. In the histology-specific analysis, the risk of the oral cavity and pharynx, urinary system and all lymphatic and hematopoietic diseases was not significantly influenced in LCNEC patients and increased in SCLC cases.

The risk of second cancers following lung HGNEC was higher for women than men (SIR = 1.78 \[95% CI = 1.65 to 1.91\] versus 1.32 \[95% CI = 1.22 to 1.43\]), and women had the highest SIR values irrespective of any race. SIR values decreased with age, with the uppermost SIR reported for the youngest (age \< 50 years) male cohort (SIR 5.21; 95% CI, 2.92 to 8.60). For men and women, SIR values increased with the year of initial primary lung HGNEC diagnosis (Table [3](#Tab3){ref-type="table"}). Table 3Standardized incidence ratio (SIR) analysis of SMP in patients with a history of an initial primary lung HGNEC by sex, race, age and year of diagnosis, SEER-18ObservedExpectedO/E95% CIExcess risk**Total**1361887.491.531.45--1.6283.11**Age and Sex**Male All Men619469.981.321.22--1.4359.83  \< 50152.885.212.92--8.60100.27 50--64187106.351.761.52--2.0383.72  \> 65417360.751.161.05--1.2739.99Female All Women742417.51.781.65--1.91101.19  \< 50165.382.981.70--4.8376.02 50--64207107.691.921.67--2.2080.9  \> 65519304.431.71.56--1.86116.64**Sex and Race**Male White524404.861.291.19--1.4156.6 Black6146.611.311.00--1.6860.13 Other3418.031.891.31--2.64111.65Female White663377.181.761.63--1.90100.63 Black6131.781.921.47--2.47107.75 Other188.312.171.28--3.42104.01**Sex and Year**Male 2000--20045785.790.660.50--0.86−66.4 2005--2010230184.251.251.09--1.4247.7 2011--2016332199.941.661.49--1.85120.29Female 2000--20046362.8610.77--1.280.3 2005--2010239157.771.511.33--1.7266.49 2011--2016440196.872.232.03--2.45162.62

Race and age at diagnosis {#Sec5}
-------------------------

All 3 race groups (white, black, and other) were at increased risk of SPM development (white: SIR 1.52, 95% CI, 1.43 to 1.61; black: SIR 1.56, 95% CI, 1.29 to 1.86; and other: SIR 1.97, 95% CI, 1.47 to 2.59). The risks of SPMs in the respiratory system were elevated across all race groups (Table [4](#Tab4){ref-type="table"}). Whites were found to have a significantly elevated risk of SPM of the floor of mouth (SIR 8.11; 95% CI, 3.50 to 15.98), and oropharynx (SIR 5.90; 95% CI, 1.61 to 15.09). In the black racial subgroup, the risk of an SPM was highest in the adrenal gland (SIR 41.01; 95% CI, 1.04 to 228.51), followed by gum and other mouth (SIR 9.10; 95% CI, 1.10 to 32.89), and esophagus (SIR 4.50; 95% CI, 1.23 to 11.52). In the other racial subgroup, the risk of developing an SPM in the digestive system was not significantly altered (SIR 0.66; 95% CI, 0.21 to 1.54), but their risk of SPMs for oropharynx was markedly increased (SIR 69.80; 95% CI, 1.77 to 388.92). Table 4Risk of SPM after lung HGNEC, stratified by raceObservedExpectedO/E95% CIExcess risk**White**All Sites1187782.041.521.43--1.6181.89All Solid Tumours1080695.271.551.46--1.6577.8Oral Cavity and Pharynx2617.871.450.95--2.131.64 Floor of Mouth80.998.113.5--15.981.42 Oropharynx40.685.91.61--15.090.67Digestive System195140.51.391.20--1.6011.02 Splenic Flexure51.63.131.02--7.300.69 Pancreas4022.391.791.28--2.433.56Respiratory System568127.474.464.10--4.8489.08Breast78110.420.710.56--0.88−6.56Female Genital System1742.440.40.23--0.64−5.14Male Genital System46120.80.380.28--0.51−15.13Urinary System10268.891.481.21--1.806.7 Urinary Bladder6241.771.481.14--1.904.09 Kidney3623.491.531.07--2.122.53All Lymphatic and Hematopoietic Diseases8467.831.240.99--1.533.27 Leukemia5921.462.752.09--3.557.59**Black**All Sites12278.391.561.29--1.8685.42All Solid Tumours11470.911.611.33--1.9384.42Oral Cavity and Pharynx21.551.290.16--4.670.89 Gum and Other Mouth20.229.11.1--32.893.49Digestive System2716.981.591.05--2.3119.62 Esophagus40.894.51.23--11.526.09Respiratory System5413.174.13.08--5.3579.97Male Genital System1018.970.530.25--0.97−17.58Kidney72.742.551.03--5.268.34Adrenal Gland10.0241.011.04--228.511.91Leukemia41.482.70.73--6.914.93**Other (American Indian/AK Native, Asian/Pacific Islander)**All Sites5226.331.971.47--2.59108.64All Solid Tumours4723.61.991.46--2.6599.04 Oral Cavity and Pharynx20.623.240.39--11.75.85 Pharynx20.1910.471.27--37.817.66 Oropharynx10.0169.81.77--388.924.17Digestive System57.560.660.21--1.54−10.82Respiratory System284.236.634.4--9.58100.62Leukemia30.565.41.11--15.7710.34

Overall risk was negatively correlated with age (20--49 years: SIR 3.75, 95% CI, 2.55 to 5.33; 50--64 years: SIR 1.84, 95% CI, 1.66 to 2.03; 65+ years: SIR 1.41, 95% CI, 1.32 to 1.50, Fig. [1](#Fig1){ref-type="fig"}). All 3 age groups had an elevated risk of developing SPMs in the digestive system and respiratory system (Table [5](#Tab5){ref-type="table"}). Subgroup analysis suggested that younger patients had an increased risk of SPMs of the pancreas (SIR 41.88; 95% CI, 13.60 to 97.74), floor of mouth (SIR 81.76; 95% CI, 2.07 to 455.51), gum and other mouth (SIR 40.99; 95% CI, 1.04 to 228.4), and respiratory system (SIR 12.41; 95% CI, 4.99 to 25.58). Older patients were at greater risk of malignancies of acute myeloid leukemia (SIR 5.65; 95% CI, 3.87 to 7.98), floor of mouth (SIR 5.48; 95% CI, 1.49 to 14.04), ascending colon (SIR 2.15; 95% CI, 1.35 to 3.25), respiratory system (SIR 3.90; 95% CI, 3.55 to 4.28), and urinary system (SIR 1.37; 95% CI, 1.09 to 1.69). Fig. 1Observed/expected (O/E) incidence and absolute excess rate (AER) for second primary malignancies (SPMs) by patient age at the time of lung HGNEC diagnosisTable 5Risk of SPM after lung HGNEC, stratified by ageObservedExpectedO/E95% CIExcess risk**\< 50 years**All Sites318.263.752.55--5.3387.27All Solid Tumours287.443.762.5--5.4478.9Oral cavity and pharynx20.258.070.98--29.166.72 Floor of Mouth10.0181.762.07--455.513.79 Gum and Other Mouth10.0240.991.04--228.43.74Digestive System81.26.662.88--13.1226.09 Colon, Rectum and Anus30.724.140.85--12.18.73 Pancreas50.1241.8813.6--97.7418.73Respiratory System70.5612.414.99--25.5824.7 Lung and Bronchus70.4914.225.72--29.324.97Miscellaneous20.0921.212.57--76.627.31**50--64 years**All Sites394214.041.841.66--2.0382.14All Solid Tumours361194.611.861.67--2.0675.95Oral cavity and pharynx136.262.081.11--3.553.08 Floor of Mouth30.378.131.68--23.761.2 Pharynx40.924.351.18--11.131.41 Oropharynx40.2714.734.01--37.711.7Digestive System6236.561.71.3--2.1711.61 Esophagus72.143.271.31--6.732.22 Small Intestine41.043.831.04--9.811.35 Ascending Colon61.933.111.14--6.771.86 Pancreas174.973.421.99--5.485.49Respiratory System18627.276.825.88--7.8872.45 Lung and Bronchus18024.947.226.2--8.3570.77Male Genital System1536.560.410.23--0.68−9.84 Prostate1436.090.390.21--0.65−10.08Urinary System3214.842.161.47--3.047.83 Urinary Bladder156.922.171.21--3.573.69 Kidney177.42.31.34--3.684.38All Lymphatic and Hematopoietic Diseases2815.751.781.18--2.575.59 Leukemia244.525.323.41--7.918.89 Acute Lymphocytic Leukemia30.2412.482.57--36.481.26 Non-Lymphocytic Leukemia182.088.675.14--13.77.27 Acute Non-Lymphocytic Leukemia161.3611.756.72--19.086.68 Myeloid and Monocytic Leukemia181.949.295.51--14.687.33 Acute Myeloid Leukemia141.2311.46.23--19.135.83 Acute Monocytic Leukemia20.0824.432.96--88.230.88**\> 65 years**All Sites936665.191.411.32--1.583.43All Solid Tumours852588.371.451.35--1.5581.22Oral cavity and pharynx1513.551.110.62--1.830.45 Floor of Mouth40.735.481.49--14.041.01Digestive System157127.411.231.05--1.449.12 Colon, Rectum and Anus9767.291.441.17--1.769.15 Colon and Rectum9165.221.41.12--1.717.94 Colon excluding Rectum7749.11.571.24--1.968.6 Ascending Colon2210.232.151.35--3.253.62Respiratory System457117.153.93.55--4.28104.7 Lung and Bronchus440111.173.963.6--4.35101.3Breast4982.130.60.44--0.79−10.21Female Genital System1030.690.330.16--0.6−6.37 Corpus and Uterus, NOS217.050.120.01--0.42−4.64Male Genital System44107.80.410.3--0.55−19.65 Prostate43106.870.40.29--0.54−19.68Urinary System8360.721.371.09--1.696.86All Lymphatic and Hematopoietic Diseases6659.421.110.86--1.412.03 Leukemia4218.822.231.61--3.027.14 Non-Lymphocytic Leukemia379.313.972.8--5.488.53 Acute Non-Lymphocytic Leukemia346.315.393.73--7.538.53 Myeloid and Monocytic Leukemia378.444.393.09--6.048.8 Acute Myeloid Leukemia325.665.653.87--7.988.11

Histology {#Sec6}
---------

Five hundred and eighty-two patients developed one or more second primary lung cancers (SPLCs). The various histological types of SPLC were assessed within each subset of the lung HGNEC (Table [6](#Tab6){ref-type="table"}). Squamous cell carcinoma was the most common subtype, and a higher proportion was observed following SCLC. Conversely, initial primary LCNECs most presented with SPLC adenocarcinoma (40%). Only 15% of SPLCs were SCLC, which is similar to the incidence of SCLC in the general population. Among the study population, 74% of patients who developed SPLCs initially had regional and distant stage, but only 22% had localized stage. More than half of those SPLCs (55%) presented at advanced or unknown stage, while only 45% had localized disease. Table 6Distribution of histology and stage in second primary lung cancer (SPLC) patients with history of an initial primary lung HGNECSPLC HistologySmall cellOther or unknownTotalSquamous cellAdenocarcinoma**HGNEC Histology**NRow(%)NRow(%)NRow(%)NRow(%) SCLC20638%14126%8115%11421%542 LCNEC2023%3440%1619%1518%85Total22636%17528%9715%12921%627**SPLC Stage**LocalizedRegionalDistantUnstagedTotal**HGNEC Stage**NRow(%)NRow(%)NRow(%)NRow(%) Localized7151%3223%3424%32%140 Regional13044%7124%8629%93%296 Distant6841%4024%5231%74%167 Unstaged1250%417%729%14%24Total28145%14723%17929%203%627

SPM and latency {#Sec7}
---------------

The incidence of developing SPMs was relatively high after 12 months of lung HGNEC diagnosis and then increased, with significantly difference from that of the general population (Fig. [2](#Fig2){ref-type="fig"}). The risk of oropharyngeal cancer (SIR 9.22; 95% CI, 1.12 to 33.31), and kidney cancer (SIR 2.24; 95% CI, 1.28 to 3.63) was much higher within 6--11 months of the index diagnosis. However, no significant risk of SPM was found in other latency intervals. The risk of mouth floor cancer (SIR 6.90; 95% CI, 1.88 to 17.66), leukemia (SIR 3.84; 95% CI, 2.81 to 5.13), and ascending colon cancer (SIR 2.23; 95% CI, 1.22 to 3.74) was greatly increased within 12--59 months of latency compared to the general population. Significant increases in the risk for cancers of the digestive system and respiratory system also existed 12 months or more after the index diagnosis. The risk of SPM for each latency period is shown in Table [7](#Tab7){ref-type="table"}. Fig. 2Observed/expected (O/E) incidence (standardized incidence ratio, SIR) of second primary malignancies (SPMs) by latency period after the diagnosis of lung HGNEC over timeTable 7Risk of SPM after lung HGNEC, stratified by latency6--11 months95% CIExcess risk12--59 months95% CIExcess risk60--119 monthsExcess risk120+ monthsExcess riskOEO/EOEO/EOEO/E95% CIOEO/E95% CIAll Sites174236.630.740.63--0.85−40.5679458.531.481.37--1.673.86380152.972.482.24--2.75241.9412839.353.252.71--3.87389.58All Solid Tumours162211.360.770.65--0.89−31.91603408.911.471.36--1.665.02356135.522.632.36--2.91234.9512034.633.472.87--4.14375.2Oral Cavity and Pharynx95.451.650.75--3.132.291410.31.360.74--2.281.2453.421.460.47--3.411.6820.882.260.27--8.164.9Digestive System5343.961.210.9--1.585.8410585.11.231.01--1.496.675128.641.781.33--2.3423.82187.462.411.43--3.8146.33Respiratory System3438.640.880.61--1.23−331774.794.243.78--4.7381.1422225.038.877.74--10.12209.9776.5211.819.32--14.76309.74Breast1530.340.490.28--0.82−9.923964.320.610.43--0.83−8.482621.861.190.78--1.744.4165.661.060.39--2.311.51Female Genital System211.640.170.02--0.62−6.231224.820.480.25--0.84−4.2958.470.590.19--1.38−3.712.170.460.01--2.57−5.14Male Genital System1042.930.230.11--0.43−21.293074.990.40.27--0.57−15.071221.950.550.28--0.96−10.674.971.410.57--2.98.9Urinary System2820.221.390.92--25.036238.711.61.23--2.057.82313.51.71.08--2.5610.1243.61.110.3--2.851.76All Lymphatic and Hematopoietic Diseases719.720.350.14--0.73−8.236138.791.571.2--2.027.442113.661.540.95--2.357.8263.71.620.6--3.5310.12

Overall survival and clinical characteristics {#Sec8}
---------------------------------------------

Multivariate Cox proportional hazards model was performed to determine risk factors associated with overall survival and cancer-specific survival (Table [8](#Tab8){ref-type="table"}). After adjusting for other factors, patients with regional and distant stage disease were much more likely to have an increased risk of death with HRs of 1.608 (95% CI, 1.317 to 1.964; *P* = 0.000) and 2.113 (95% CI, 1.716 to 2.602; *P* = 0.000), respectively. Patients aged ≥65 years had an elevated risk of death compared with those aged less than 65 years (HR 1.242; 95% CI, 1.085 to 1.422; *P* = 0.002). As for latency time, those patients shorter than 60 months also showed a difference in an elevated risk of death (HR 3.862; 95% CI, 3.310 to 4.507; *P* = 0.000). Beam radiation (HR 1.997; 95% CI, 1.233 to 3.237) was related to the worsening prognosis, but chemotherapy status did not have a significant association with overall survival. Variables that were significantly associated with increased cancer-specific mortality were beam radiation, regional/distant disease, and an interval of \< 60 months between the diagnosis of lung HGNEC. Table 8Cox proportional hazard regression analysis for the overall survival and cancer-specific survival of lung HGNEC patients with SPMVariableoverall survivalcancer-specific survivalHR95% CI*P*HR95% CI*P*Age  \< 65 yearReferenceReference  ≥ 65 year1.2421.085--1.4220.0020.9810.827--1.1630.824Sex MaleReferenceReference Female0.9620.843--1.0980.5690.8970.760--1.0590.198Race WhiteReferenceReference Black0.9220.727--1.1690.5030.8700.642--1.1770.366 Other1.0110.712--1.4340.9531.1370.747--1.7310.550Stage LocalizedReferenceReference Regional1.6081.317--1.9640.0001.7831.373--2.3140.000 Distant2.1131.716--2.6020.0002.3701.809--3.1030.000 Unknown/unstaged1.2300.835--1.8110.2951.1200.661--1.8980.674Radiation None/UnknownReferenceReference Beam radiation1.9971.233--3.2370.0052.2541.299--3.9090.004 Other radiation0.9910.833--1.1780.9140.9500.763--1.1820.643Chemotherapy YesReferenceReference None/Unknown0.8810.715--1.0850.2320.9150.704--1.1900.509Latency  ≥ 60 monthsReferenceReference 6--59 months3.8623.310--4.5070.0003.7613.093--4.5730.000

Discussion {#Sec9}
==========

As far as we know, this study is the first to quantify the occurrence of SPMs after pulmonary HGNEC. Our study revealed that the overall risk of SPM in patients with pulmonary HGNEC was statistically higher than that in the general population. In total, the incidence of SMPs in patients with pulmonary HGNEC is approximately 1.53%. The incidence of SPMs in patients with SCLC is 1.41%, whereas the incidence in patients with lung LCNEC is 3.98%. Going beyond prior researches, we estimated the risk of second malignancies by calculating SIRs, which were stratified by age, sex, race, latency, and histology.

A significantly elevated risk of cancer in pulmonary HGNEC was also evident in our report, especially in patients aged less than 50 years, females, other races (American Indian/AK Native, Asian/Pacific Islander), patients with longer latency periods and LCNEC patients. The SIRs in females were found to be higher than their male counterparts, even though pulmonary HGNEC are less common in the female than male. It is estimated that the incidence of SCLC varied by gender, with a lower frequency in females. Survival was superior to women, indicating genomic incompatibility between the sexes \[[@CR6]\]. Carcinogens in cigarette smoke have been hypothesized to preferentially bind to estrogen receptors, thereby inhibiting their carcinogen activation reactions \[[@CR7]\]. Furthermore, it has been shown that the use of hormone replacement therapy decreased lung cancer risk in females, especially in female never smokers \[[@CR8]\]. Females may be more likely to survive longer and have access to develop an SPM. These factors may potentially explain the higher SIRs and the lower risk of females. However, younger males had the highest SIR. This may be relevant to the declining overall cancer incidence among younger males. A review of the existing studies shows that there are twice as many women as men in younger cancer patients \[[@CR9]\]. Thus, the difference between the observed and expected risk of developing cancers in younger males will be greater. Furthermore, the incidence of SPMs increased with age. These results confirmed those of Deng et al. who found increased age as a negative survival predictor in patients with LCNEC \[[@CR10]\].

We observed that lung HGNEC survivors, particularly SCLC survivors, were less likely to develop cancers of the breast, female genital system, and prostate. In contrast, patients with lung HGNEC had elevated risks of getting leukemia and cancers of the oral cavity and pharynx, colon and rectum, esophagus, pancreas, urinary bladder, kidney and renal pelvis, and lung and bronchus. Cancer risk reduction in these patients is consistent with prior researches, which are relevant to lung cancer and non-small cell lung cancer \[[@CR11], [@CR12]\]. Although the causes of risk reduction are not well understood, they may be associated with patient age at diagnosis of SCLC. The current incidence of SCLC was highest in the 65--79 age group, and the number of SCLC patients decreased in most age groups over the past few decades, primarily because of public awareness about smoking and comprehensive tobacco control programs \[[@CR6]\]. Nevertheless, older patients who have SCLC may not have an equal opportunity for an SPM as the total population of the United States. Conversely, the increased rate of certain cancers following primary lung HGNEC seems to be attributed to smoking. Lung HGNEC patients had a greater risk of developing respiratory system cancer in all age groups. This correlation was also evident in a subgroup analysis of the younger populations below the age of 50 years.

Other considerations are more deliberate surveillance and molecular mutation. Once patients are newly diagnosed with cancer, they may receive more monitoring. In most lung HGNEC, only a few genes were found to be mutated regularly. Tumour suppressor protein 53 (TP53) and retinoblastoma 1 (RB1), which are strongly associated with smoking, are mutated in nearly all SCLC \[[@CR13], [@CR14]\] and most of these lung LCNEC \[[@CR15]\]. Even so, no targeted therapy could be translated from basic research to standard treatment until now. Smoking is also a risk factor for HPV-negative head and neck squamous cell carcinoma. Mutations are more frequent in these tumours from smokers than non-smokers. TP53 mutations are more common in HPV-negative tumours and have been related to poor survival and therapeutic resistance \[[@CR16]\]. This may be relevant to the increased rate of the oral cavity and pharynx cancer observed in our SCLC cohort, so patients with SCLC would necessarily be expected to have closer surveillance for these smoking-related malignancies. Many studies showed that acute myeloid leukemia and lung HGNEC have the same c-Kit high expression. Positivity expression of c-Kit is observed in 49% of LCNEC and 47% of SCLC cases \[[@CR17]\], and the frequency of positive c-Kit among acute myeloid leukemia was about 80% \[[@CR18]\]. However, there is no evidence to suggest that these two tumours are closely linked. Similarly, the relationship between lung HGNEC and acute myeloid leukemia has not been covered.

In lung cancers following pulmonary HGNEC, 74% of SPLCs were found to be adenocarcinoma and squamous cell carcinoma. Much higher rates of squamous cell carcinoma were detected relative to the SCLC subset. To our knowledge, squamous and small cell histology are the most strongly related to smoking. This study supports our understanding of SCLC most closely linked to smoking \[[@CR19]\]. Interestingly, lung cancers following lung LCNEC were much more likely to be of adenocarcinoma histology. However, based on currently observed data, we cannot identify the relationship between these two cancers. Thus, there is a need for advanced assessment techniques such as gene expression to provide information for patients and clinicians.

Multivariate Cox regression model revealed that older patients, advanced historical stage, beam radiation history, and shorter latency time were associated with increased risk of developing the SPMs in lung HGNEC patients. Our data found a higher risk of developing the SPMs to be in those aged more than 65. As expected, this is likely because older patients have a higher probability of developing invasive cancer. In addition, lung HGNEC has a high risk of death in the regional and distant stage. Beam radiation was strongly associated with increased overall mortality. A study demonstrated that radiotherapy, in combination with chemotherapy has been described as having an additive effect on the occurrence of secondary cancer \[[@CR20]\]. However, our paper could not confirm this finding. Currently, there is no report about the long-term cause of death in patients with lung HGNEC. We also use the HR of cancer-specific survival to determine the impact of SPM on pulmonary HGNEC patients. The risk of cancer-specific mortality did not increase with age. This is because older patients are more likely to die of other diseases such as cardiovascular disease.

The advantages of this research include a large sample size, which strengthens the generalizability of the findings. However, there are some limitations of the current study. The cross-sectional limitations rely on the retrospective nature and inherent limitations of publicly-accessible databases, such as the lack of treatment details (radiation dosage, surgery type), family history, and lifestyle factors (smoking). Half of the data in some variables, such as grade, is unknown. These factors would affect the comprehensive analysis of risk factors for SPM development. Also, our analysis may have missed patients who change their living place throughout the follow-up period. Once they have SPMs, these details were not registered in the SEER database. Finally, germline mutations are not provided by the SEER database. Further research is required to identify the appropriate screening/surveillance recommendations and to clarify potential genetic factors that may lead to increased cancer risk for these patients.

Conclusions {#Sec10}
===========

The risk of SPM is significantly higher among lung HGNEC than the U.S. general population. The most common and biologically meaningful were acute monocytic leukemia, acute myeloid leukemia, and floor of mouth tumours, but an elevated risk for lung and oropharynx cancers was also demonstrated. Old age, advanced stage, beam radiation, and shorter latency time were identified as negative prognostic factors. Chemotherapy did not substantially influence the incidence of SPMs, which can be traced to the lack of adequate data. The observed increased risk may be explained by genetic susceptibility and lifestyle modifications. With the ongoing improvement in the long-term survival of patients with lung HGNEC, evaluation for SPMs will become even more crucial in the follow-up care of these patients.

HGNEC

:   High-grade neuroendocrine carcinoma

SPM

:   Second primary malignancy

SEER

:   Surveillance, Epidemiology and End Results

SIR

:   Standardized incidence ratio

AER

:   Absolute excess risk

SLCL

:   Small cell lung cancer

LCNEC

:   Large cell neuroendocrine carcinoma

OS

:   Overall survival

CSS

:   Cancer-specific survival

HR

:   Hazards ratio

CI

:   Confidence interval
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:   Second primary lung cancer

TP53

:   Tumour suppressor protein 53
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